Carolyn M. Setze

An Interferon-free Antiviral Regimen for HCV after Liver Transplantation

Paul Y. Kwo, Parvez Mantry, Eoin Coakley et al. · New England Journal of Medicine · 2014 · 402 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

Hiromitsu Kumada, Kazuaki Chayama, Lino Rodrigues et al. · Hepatology · 2015 · 153 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A

Preethi Krishnan, Jill Beyer, Neeta Mistry et al. · Antimicrobial Agents and Chemotherapy · 2014 · 131 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study

Peter H. Jones, Michael H. Davidson, Moti L. Kashyap et al. · Atherosclerosis · 2008 · 91 citations

Pharmacy, Pharmacology, Pharmacotherapy +10

Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients

Kazuaki Chayama, Kazuo Notsumata, Masayuki Kurosaki et al. · Hepatology · 2015 · 82 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17